Business Context and Reporting Period
Company: Neuphoria Therapeutics Inc. (formerly Bionomics Limited)
Reporting Period: Quarterly period ended December 31, 2025 (Six months ended December 31, 2025)
Business Overview: Neuphoria is a clinical-stage biotechnology company focused on developing therapies for neuropsychiatric disorders. Its lead candidate, BNC210, targets PTSD and social anxiety disorder (SAD). The company recently re-domiciled from Australia to Delaware in December 2024.
Current Status: Following the failure of the AFFIRM-1 Phase 3 trial for SAD in October 2025, the company discontinued the SAD program and paused the PTSD program. Management initiated a comprehensive strategic review to identify potential mergers or partnerships. As part of cost-cutting measures, the company terminated all but one employee and exited its Australian facility.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2024 |
|---|---|---|
| Revenue | $0 | $662,715 |
| Net Income (Loss) | $(8,042,412) | $(2,748,136) |
| Net Income (Loss) - Three Months | $1,864,092 | $(1,943,349) |
| Operating Expenses | $9,713,502 | $7,933,953 |
| Research & Development | $4,483,372 | $3,637,942 |
| General & Administrative | $3,993,958 | $4,296,011 |
| Restructuring Costs | $1,236,172 | $0 |
| Cash and Cash Equivalents (Dec 31, 2025) | $22,170,414 | N/A |
| Net Cash Used in Operating Activities | $(10,230,463) | $(7,791,150) |
| Net Cash Provided by Financing Activities | $17,915,883 | $(338,900) |
| Accumulated Deficit | $(186,389,115) | N/A |
Other Key Items: The company recorded a significant non-cash gain of $5.38 million on fair value adjustments (primarily warrant liability) in the three months ended December 31, 2025, which drove the quarterly net income despite operating losses.
Material Changes vs. Prior Period
- Revenue: Revenue dropped to zero for the six months ended December 31, 2025, compared to $662,715 in the prior year period. The prior period revenue was driven by a milestone payment from Carina Biotech in October 2024.
- Restructuring: The company incurred $1.24 million in restructuring costs in the current period, primarily due to employee termination costs ($1.41 million) and lease write-offs, partially offset by refundable credits ($0.62 million). No such costs were recorded in the prior period.
- Operating Expenses: Total operating expenses increased by approximately $1.78 million year-over-year, driven by the inclusion of restructuring costs and increased R&D spend related to the SAD trial prior to its discontinuation.
- Other Income: Other income decreased significantly on a six-month basis ($1.60 million vs. $4.40 million) due to a lower fair value adjustment gain on warrant liabilities compared to the prior year.
- Liquidity: Cash and cash equivalents increased from $14.2 million at June 30, 2025, to $22.2 million at December 31, 2025, primarily due to $17.9 million in proceeds from equity sales via the ATM facility.
Guidance, Outlook, and Risks
Strategic Review: The company is actively reviewing strategic alternatives, including mergers, acquisitions, or partnerships, to maximize shareholder value. It has engaged H.C. Wainwright & Co. and WG Partners as advisors. The board rejected a revised non-binding acquisition proposal from Lynx1 Master Fund LP at $4.75 per share as undervalued.
Outlook: Management believes existing cash resources ($22.2 million) are sufficient to fund operations beyond the third quarter of fiscal year 2027, assuming continued cost curtailments. The company has paused clinical development of BNC210 for PTSD pending the outcome of the strategic review.
Risks and Contingencies:
- Clinical Failure: The failure of the Phase 3 SAD trial eliminates a key near-term revenue opportunity and increases reliance on a strategic transaction.
- Going Concern: While management currently asserts no substantial doubt regarding the ability to continue as a going concern for the next 12 months, this is contingent on the success of the strategic review or the ability to raise additional capital.
- Shareholder Rights Plan: A poison pill (Rights Plan) was adopted in October 2025 to protect against unsolicited takeovers, expiring October 2026.
- Leadership Transition: The CEO, Dr. Spyridon Papapetropoulos, transitioned to an interim consulting role effective January 1, 2026, following the termination of his employment agreement.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the $22.2 million cash balance and the assumptions behind the "beyond Q3 FY2027" runway projection given the paused operations.
- Strategic Process: Monitor updates on the strategic review process, specifically any definitive agreements or new acquisition proposals.
- Warrant Liability: Understand the impact of the $2.7 million warrant liability on the balance sheet and how future stock price movements could affect net income/loss via fair value adjustments.
- Restructuring Completion: Confirm that all restructuring payments (severance, lease terminations) are fully accrued and that no further significant one-time costs are expected.
- ATM Facility Usage: Review the terms and remaining capacity of the At-The-Market (ATM) facility used to raise $17.9 million in the period.